Blonanserin vs risperidone in Japanese patients with schizophrenia: A post hoc analysis of a phase 3, 8‐week, multicenter, double‐blind, randomized controlled study
Pharmacology, Toxicology and Pharmaceutical Science
3
5%
Biochemistry, Genetics and Molecular Biology
2
4%
Nursing and Health Professions
2
4%
Psychology
2
4%
Other
3
5%
Unknown
33
60%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 January 2026.
All research outputs
#21,660,283
of 34,411,289 outputs
Outputs from NEUROPSYCHOPHARMACOLOGY REPORTS
#159
of 627 outputs
Outputs of similar age
#299,353
of 524,550 outputs
Outputs of similar age from NEUROPSYCHOPHARMACOLOGY REPORTS
#3
of 13 outputs
Altmetric has tracked 34,411,289 research outputs across all sources so far. This one is in the 36th percentile – i.e., 36% of other outputs scored the same or lower than it.
So far Altmetric has tracked 627 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.8. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 524,550 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.
